Von Willebrand disease is a lifelong bleeding disorder in which your blood doesn't clot well. Some people may suspect they have a bleeding disorder when they have heavy bleeding after a dental procedure. Mutations in the von Willebrand disease gene cause von Willebrand disease. The von Willebrand factor as a blood clotting protein was provided by the VWF gene and is essential for the formation of blood clots.
Introduction
Children with haematological diseases are a very important group of a dental aspect, because they are relatively often encountered in dental clinics. This particularly applies to children with haemorrhagic syndrome, who in the clinical picture have either spontaneous bleeding or bleeding after injury. Children with haemorrhagic syndrome require dentists more care than other patients because they are constantly exposed to the risk of bleeding during dental intervention. Haemorrhagic diseases are manifested by petechiae, ecchymoses, hematomas, haemarthrosis, epistaxis, haematuria and others. Many diseases in children with haemorrhagic syndrome are often manifested with characteristic changes in the mouth. This means that the dentist is the one who often first notices these changes and is therefore obliged to refer the patient to a hematologist. Of great importance for the early diagnosis and proper treatment of these diseases is the role of dentist , because the dentist may be the first one who suspect or recognize one of these diseases. It is very important to diagnose a haemorrhagic disease in the early childhood because the proper diagnosis means to provide timely preparation and to avoid the danger of the child's health and life.
Von Willebrand's disease (Vascular haemophilia) is a hereditary disease that is transmitted by an autosomal dominant gene, but also some time by an autosomal recesive gene. Women are more likely to get sick. The patients have lack of Von Willebrand's coagulation factor, which is found in plasma, platelets, megakaryocytes, and endothelial cells [1] . Von Willebrand Factor (vWF) is a large glycoprotein with a broad range of physiological and pathological functions in health and disease [2] .
Von Willebrand disease is a lifelong bleeding disorder in which your blood doesn't clot well. Some people may suspect they have a bleeding disorder when they have heavy bleeding after a dental procedure. Mutations in the von Willebrand disease gene cause von Willebrand disease. The von Willebrand factor as a blood clotting protein was provided by the VWF gene and is essential for the formation of blood clots. In fact 95-97% of all coagulation deficiencies belong to the three group of disease: Von Willebrand disease, Hemophilia A and Hemophilia B [3] .
The pathogenesis of the disease is not sufficiently clear, but it has been established that quantitative and qualitative disorders of the VIII factor which is involved in the process of blood coagulation (deficiency of the factors which affect the time of coagulation and those required for platelet adhesion and aggregation) are established. In children with vascular haemophilia, major irregularities of blood vessels can be detected [1] . The first suspect of some people with Von Willebrand disease occur when they have a bleeding disorder and they have heavy bleeding after a dental procedure or, for women, during a menstrual period.
Clinical disease is characterized by a tendency of bleeding in the early period of childhood, which manifests itself with bleeding from the skin (bruising with minimal trauma), mucous membrane of the oral cavity (gingiva), nose and mucous membrane of the digestive organs. Prolonged haemorrhage occurs in children after traumatic injuries, 
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and it must be taken into consideration that these children must be prepared by the haematologist before any oral surgical intervention was undergo [1] . 
Case Report
Boy was ten year old when with his mother come to the Department for preventive and pediatric dentistry, 
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The mother provides us with the anamnesis' data that her child previously have convulsions on two occasions. In February 2018, myringotomy procedure and adenoidectomy were made to the child, and there was no prolonged bleeding. Also an appendectomy has been made to a child four years ago. The mother denies familial history of hemorrhagic diathesis. Clinical examination of the child shows squamous scalp and initial alopecia hot spots, erythema-squamous lesions of the corpse and limbs. Consultation with a dermatologist is required.
The child was received at the Otorhinolaryngology Clinic due to frequent suppurative otitis, decreased hearing and snoring during sleeping.With the general endotracheal anesthesiaIn OETA transmeatally mirrinotomy bilaterally was done, during which plentiful serous secretion right and mucosal secretion on the left was aspirated. The ventilation tubes (Grommet-Shepard) [9] were placed and sol.Citeral. together with exact haemostasis was conducted. Then, with adenoma, excessive adenoid lymphatic tissue was removed from the epipharynx. Exact haemostasis was conducted during the intervention. Hygiene-dietary diet and rest for up to 14 days after the intervention was recommended by otolaryngology. The finding of the otomicroscopic examination was unequivocal.
Audiometric testing which was done six months after the placement of "gromets" bill shows a moderate mixed hearing loss on both ears. The patient was send to oto-microscopic examination. Subspecialist audiologist prescribed 
Discussion
This disorder is characterized by a mutation of the von Willebrand factor itself or in the quantity of the creation of the von Willebrand factor. This factor is responsible for primary haemostasis by helping platelet aggregation and adherence to the endothelial lining and acting as a carrier factor for factor VIII. Factor VIII has a significantly shortened half-life when it is not bound to Von Willebrand factor; this is the reason that factor VIII levels in Type 2M is characterized by a qualitative defect and can create appropriate multimers; however, its ability to bind to platelets is reduced. Hence, the plasma antigen levels are normal, large multimers are present, but the cofactor values are reduced.
Type 2N (N is from Normandy, where this type was first described) is a rare autosomal recessive disorder. The defect affects the ability of Von Willebrand factor to bind Factor VIII, but the factor binding factor VII remains normal (as well as the amount of available von Willebrand factor), but the factor VIII levels are greatly reduced.
Because this subtype is recessive, a split allele must be inherited in order for symptoms to occur. It may be difficult to distinguish this subtype from factor VIII deficiency (haemophilia), because in both conditions patients have low levels of factor VIII. Background Willebrand disease type 2N should be considered when the patient has a family 
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disease and plaque-induced gingivitis. They concluded that Type 2 and 3 VWD are not associated with a more pronounced inflammatory response to the oral biofilm in terms of Gingival Bleeding Index ( GBI) and bleeding on probing (BOP) [11] . In the case-control study by Weickert L, 50 patients and 40 matched controls were periodontally examined, underwent professional teeth cleaning and also answered a questionnaire. Weickert L, et al concluded that gingival bleeding in VWD patients may be caused by by gingival inflammation, but it is not a real symptom of mild type 1 VWD [12] .
In a case report by Argyris PP, et al. 11-year-old Caucasian female is presented with an surgical excision of the tumor like a expansile gingival mass, which was located on the posterior maxilla The patient suffered prolonged hemorrhage, after the intervention. Results of blood tests showed decreased levels of FVIII function (C) and VWF:FVIIIB. The type 2 N VWD was confirmed as heterozygosity for the missense mutation p.Arg816 Trp, by the subsequent gene analysis [13, 14] . In our case the genetic analysis was not preformed.
Treatment of Von Willebrand disease
There are five modalities for the treatment of von Willebrand's disease. 
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If possible, this should be avoided, due to an increased risk of transmission of viruses. Most Factor VIII concentrates do not contain a sufficient Von Willebrand factor with a high molecular weight; however, Humate-P (human antihyfilitary factor / von Willebrand factor complex) and Alphanate (antihyolytic factor) do not contain sufficient amounts. These drugs can be used with cryoprecipitate in patients with Von Willebrand disease type 2B or type 3, because they could not be treated with DDAVP. In case of significant bleeding, the goal of compensation therapy is to maintain the activity of factor VIII and Von Willebrand factor between 50 and 100 per cent for a period of three to ten days.
The use of pure von Willebrand factor or von Willebrand factor/factor VIII (vWF/FVIII) concentrate is recommended by treatment guidlines in patients with type 2 or type 3 vWD undergoing surgery, in patients with type 1 vWD undergoing surgery who are unresponsive, and in patients for whom desmopressin acetate is contraindicated [15] . Nowadays there is no consensus on the dosage and optimum levels of these factors . Castaman G et al. [16] . Complete response to desmopressin was defined as an increase of both ristocetin cofactor activity (VWF:RCo) and factor VIII coagulant activity (FVIII:C) to 50 IU/dL or higher and partial response as VWF:RCo or FVIII:C lower than 50 IU/dL after infusion, but at least 3-fold the basal level. It seem that association between the response to desmopressin and location of mutation exist within VWD patients.
In their study complete response was noted in 83% of patients. The presence of subtle multimeric abnormalities did not hamper potential clinically useful responses, as in typical type 1 VWD [16] . Response to desmopressin is influenced by the genotype and phenotype in type 1 Von Willebrand disease [16] . Treatment of von Willebrand disease with Humate-P ® [17] . For the treatment of Von Willebrand disease also replacement therapies like Humate-P and other, contraceptives, clot-stabilizing medications like Cyklokapron, Lysteda, others and drugs applied to cuts as a fibrin sealant (Tisseel VHSD) which can be placed directly on a cut and helps curtail bleeding. People with congenital hemorrhagic diatheses constitute a very small percentage of the total population and there is a lack of studies in relation with oral health aspects in hemophilia patients. Because of that fact treatment of such patients becomes a challenge to the most of dentists, because most of them have no practical experience in dealing with von Willebrand disease and other hemorrhagic disorders [18] .
Antifibrinilitic therapy with tranexamic acid (Amicar) can also be used. It prevents lysis of blood coagulants and can be particularly useful in bleeding mucous membranes. This class of drugs can be given orally or intravenously. By 
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oral administration, the drug must be administered three or four times within 24 hours (due to the short half-life of the drug) over a period of three to seven days. Topical agents such as Gelfoam (an absorption sponge made from gelatin) and Surgicel (oxidized regenerated cellulose) soaked in topical thrombin can be used for local haemostasis.
In several studies, estrogen has been found to raise levels of Von Willebrand factor in women who consume oral contraceptives and receive hormone substitution therapy. However, no study has long considered the risk / benefit ratio of hormone replacement therapy in von Willebrand's disease.
Treatment determines the clinical findings and the extent of bleeding. There are no good laboratory analyzes that correspond to the extent of the disease. The von Willebrand factor is not a reliable marker for the degree, because this value can artificially elevate in certain physiological conditions, such as stress and pregnancy, and therefore a history of bleeding is an important indication of the extent of the disease and the determination of optimal therapy.
Conclusion
For successful extraction of the primary teeth in patient with von Willebrand disease consultation with a haematologist is necessary. Improvement in communication among hematologists, dental specialists who work at hospitals and those in paediatric dental practices could be very important to establish an effective dental management of patients with Von Willebrand disease. There is a lack of epidemiological studies about the oral health status of patients with Von Willebrand disease.
